Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells

被引:87
|
作者
Huo, Wenying [1 ,2 ,3 ,5 ,6 ]
Zhao, Guannan [1 ,2 ]
Yin, Jinggang [4 ]
Ouyang, Xuan [1 ,2 ]
Wang, Yinan [1 ,2 ]
Yang, Chuanhe [1 ,2 ]
Wang, Baojing [1 ,2 ]
Dong, Peixin [7 ]
Wang, Zhixiang [5 ]
Watari, Hidemichi [8 ]
Chaum, Edward [4 ]
Pfeffer, Lawrence M. [1 ,2 ]
Yue, Junming [1 ,2 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN USA
[2] Univ Tennessee, Hlth Sci Ctr, Ctr Canc Res, Memphis, TN USA
[3] Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN USA
[4] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN USA
[5] Henan Agr Univ, Zhengzhou, Peoples R China
[6] Henan Univ Anim Husb & Econ, Zhengzhou, Peoples R China
[7] Hokkaido Univ, Dept Womens Hlth Educ Syst, Sch Med, Sapporo, Hokkaido, Japan
[8] Hokkaido Univ, Sch Med, Dept Gynecol, Sapporo, Hokkaido, Japan
来源
JOURNAL OF CANCER | 2017年 / 8卷 / 01期
关键词
miR-21; CRISPR/Cas9; lentiviral vector; ovarian cancer; EMT; COLON-CANCER; EXPRESSION; APOPTOSIS; PATHWAY; EMT;
D O I
10.7150/jca.16723
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) mediated genome editing is a powerful approach for loss of function studies. Here we report that lentiviral CRISPR/Cas9 vectors are highly efficient in introducing mutations in the precursor miRNA sequence, thus leading to the loss of miRNA expression and function. We constructed four different lentiviral CRISPR/Cas9 vectors that target different regions of the precursor miR-21 sequence and found that these lentiviral CRISPR/Cas9 miR-21 gRNA vectors induced mutations in the precursor sequences as shown by DNA surveyor mutation assay and Sanger sequencing. Two miR-21 lentiviral CRISPR/Cas9 gRNA vectors were selected to probe miR-21 function in ovarian cancer SKOV3 and OVCAR3 cell lines. Our data demonstrate that disruption of pre-miR-21 sequences leads to reduced cell proliferation, migration and invasion. Moreover, CRISPR/Cas9-mediated miR-21 gene editing sensitizes both SKOV3 and OVCAR3 cells to chemotherapeutic drug treatment. Disruption of miR-21 leads to the inhibition of epithelial to mesenchymal transition (EMT) in both SKOV3 and OVCAR3 cells as evidenced by the upregulation of epithelial cell marker E-cadherin and downregulation of mesenchymal marker genes, vimentin and Snai2. The miR-21 target genes PDCD4 and SPRY2 were upregulated in cells transduced with miR-21gRNAs compared to controls. Our study indicates that lentiviral CRISPR/Cas9-mediated miRNA gene editing is an effective approach to address miRNA function, and disruption of miR-21 inhibits EMT in ovarian cancer cells.
引用
收藏
页码:57 / 64
页数:8
相关论文
共 50 条
  • [21] Engineering Single-Cycle Measles Vector for CRISPR/Cas9 Gene Editing
    Rallabandi, Naga Sai Ramya
    Sharp, Brenna
    Majerus, Spencer
    Hoffer, Sarriana
    Mia, Ikeda
    Devaux, Patricia
    MOLECULAR THERAPY, 2024, 32 (04) : 109 - 109
  • [22] Highly Efficient Sendai Virus Mediated CRISPR/CAS9 Gene Editing in Hematopoietic Stem Cells
    Park, Arnold
    Watkinson, Ruth
    Pernet, Olivier
    Thibault, Patricia
    Hong, Patrick
    An, Dong Sung
    Lee, Benhur
    MOLECULAR THERAPY, 2017, 25 (05) : 136 - 137
  • [23] CRISPR/Cas9 Gene Editing of HeLa Cells to Tag Proteins with mNeonGreen
    Surve, Sachin
    Sorkin, Alexander
    BIO-PROTOCOL, 2022, 12 (10):
  • [24] A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
    Chen, Xin-Zhu
    Guo, Rong
    Zhao, Cong
    Xu, Jing
    Song, Hang
    Yu, Hua
    Pilarsky, Christian
    Nainu, Firzan
    Li, Jing-Quan
    Zhou, Xin-Ke
    Zhang, Jian-Ye
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
    Si-Wei Wang
    Chao Gao
    Yi-Min Zheng
    Li Yi
    Jia-Cheng Lu
    Xiao-Yong Huang
    Jia-Bin Cai
    Peng-Fei Zhang
    Yue-Hong Cui
    Ai-Wu Ke
    Molecular Cancer, 21
  • [26] Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
    Wang, Si-Wei
    Gao, Chao
    Zheng, Yi-Min
    Yi, Li
    Lu, Jia-Cheng
    Huang, Xiao-Yong
    Cai, Jia-Bin
    Zhang, Peng-Fei
    Cui, Yue-Hong
    Ke, Ai-Wu
    MOLECULAR CANCER, 2022, 21 (01)
  • [27] Engineered Nanomaterials to Potentiate CRISPR/Cas9 Gene Editing for Cancer Therapy
    Yi, Ke
    Kong, Huimin
    Lao, Yeh-Hsing
    Li, Di
    Mintz, Rachel L.
    Fang, Tianxu
    Chen, Guojun
    Tao, Yu
    Li, Mingqiang
    Ding, Jianxun
    ADVANCED MATERIALS, 2024, 36 (13)
  • [28] Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment
    Jiang, Chunyang
    Meng, Lingxiang
    Yang, Bingjun
    Luo, Xin
    CLINICAL GENETICS, 2020, 97 (01) : 73 - 88
  • [30] CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
    Ma, Linyuan
    Jang, Lydia
    Chen, Jian
    Song, Jun
    Yang, Dongshan
    Zhang, Jifeng
    Chen, Y. Eugene
    Xu, Jie
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2019, (148):